The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...

The plans could be announced as soon as within a day, people familiar with the matter said, if the administration goes ahead.

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

George House Trust, which helps people across Greater Manchester and Liverpool, was one of 10 winners of the 2025 GSK Impact Awards ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

Biopharma deal activity climbed in early 2025, reaching $37.38 billion in the first two months, up from $35.66 billion a year ago. February saw $8.76 billion in deals, down 69% from January’s $28.63 ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...